Bristol Myers Squibb Tests New Protein Degradation Cancer Drug In Humans [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Bristol-Myers Squibb (NYSE:BMY) and Evotec have advanced molecular glue candidate BMS-986506 into Phase 1 trials for clear cell renal cell carcinoma. The program marks the first clinical-stage asset from their protein degradation collaboration and triggers a milestone payment to Evotec. The first in human study brings a new CELMoD approach into clinical testing for a difficult to treat kidney cancer subtype. Bristol-Myers Squibb, trading at $59.37, is adding another experimental therapy to its pipeline with BMS-986506 entering Phase 1. NYSE:BMY shows an 11.1% return year to date and a 16.2% return over five years, reflecting a mixed but generally positive longer term profile. For investors, this new trial adds another point of interest alongside the company's existing oncology and immunology portfolio. The Phase 1 start for BMS-986506 provides another data point to watch related to Bristol-Myers Squibb's efforts in targeted protein degradation. As the trial progresses, factor
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity [Yahoo! Finance]Yahoo! Finance
- BioIVT to Showcase ADME-Tox and NAMs Expertise at Spring 2026 Industry Events [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026Business Wire
- Don't Miss This 14% Yield And This Pharma Value Stock [Seeking Alpha]Seeking Alpha
- Bristol-Myers Squibb: The Boring Dividend Stock I'd Happily Hold Through Any Crash [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- BMY's page on the SEC website